FASN and neoplasm: One study looked at several TNBC cell lines (including developed doxorubicin-resistant TNBC cell lines) and 29 primary tumours and reported the overexpression of fatty acid synthase (FASN) in TNBC; with FASN inhibitors being used as adjuvants to achieve significant therapeutic benefits [69].